Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F22%3A00076619" target="_blank" >RIV/00159816:_____/22:00076619 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/22:00076619 RIV/00216224:14110/22:00128072

Výsledek na webu

<a href="https://www.mdpi.com/1648-9144/58/10/1477" target="_blank" >https://www.mdpi.com/1648-9144/58/10/1477</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/medicina58101477" target="_blank" >10.3390/medicina58101477</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry

Popis výsledku v původním jazyce

Background and Objectives: The aim of this paper is to evaluate the impact of humoral substance mid-regional pro-adrenomedullin (MR-proADM) on the two-year survival of patients with chronic heart failure and relate it to the dosage of furosemide. Materials and Methods: The data is taken from the stable systolic heart failure (EF &lt; 50%) FAR NHL registry (FARmacology and NeuroHumoraL activation). The primary endpoint at two-year follow-up was death, heart transplantation, or LVAD implantation. Results: A total of 1088 patients were enrolled in the FAR NHL registry; MR-proADM levels were available for 569 of them. The mean age was 65 years, and 81% were male. The aetiology of HF was ischemic heart disease in 53% and dilated cardiomyopathy in 41% of patients. The mean EF was 31 +/- 9%. Statistically significant differences (p &lt; 0.001) were obtained in several parameters: patients with higher MR-proADM levels were older, rated higher in NYHA class, suffered more often from lower limb oedema, and had more comorbidities such as hypertension, atrial fibrillation, diabetes, and renal impairment. MR-proADM level was related to furosemide dose. Patients taking higher doses of diuretics had higher MR-proADM levels. The mean MR-proADM level without furosemide (n = 122) was 0.62 (+/- 0.55) nmol/L, with low dose (n = 113) 1-39 mg/day was 0.67 (+/- 0.30) nmol/L, with mid dose (n = 202) 40-79 mg/day was 0.72 (+/- 0.34) nmol/L, with high dose (n = 58) 80-119 mg/day was 0.85 (+/- 0.40) nmol/L, and with maximum dose (n = 74) &gt;= 120 mg/day was 1.07 (+/- 0.76) nmol/L, p &lt; 0.001. Patients with higher MR-proADM levels were more likely to achieve the primary endpoint at a two-year follow-up (p &lt; 0.001) according to multivariant analysis. Conclusions: Elevated plasma MR-proADM levels in patients with chronic heart failure are associated with an increased risk of death and hospitalization. Higher MR-proADM levels in combination with increased use of loop diuretics reflect residual congestion and are associated with a higher risk of severe disease progression.

Název v anglickém jazyce

Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry

Popis výsledku anglicky

Background and Objectives: The aim of this paper is to evaluate the impact of humoral substance mid-regional pro-adrenomedullin (MR-proADM) on the two-year survival of patients with chronic heart failure and relate it to the dosage of furosemide. Materials and Methods: The data is taken from the stable systolic heart failure (EF &lt; 50%) FAR NHL registry (FARmacology and NeuroHumoraL activation). The primary endpoint at two-year follow-up was death, heart transplantation, or LVAD implantation. Results: A total of 1088 patients were enrolled in the FAR NHL registry; MR-proADM levels were available for 569 of them. The mean age was 65 years, and 81% were male. The aetiology of HF was ischemic heart disease in 53% and dilated cardiomyopathy in 41% of patients. The mean EF was 31 +/- 9%. Statistically significant differences (p &lt; 0.001) were obtained in several parameters: patients with higher MR-proADM levels were older, rated higher in NYHA class, suffered more often from lower limb oedema, and had more comorbidities such as hypertension, atrial fibrillation, diabetes, and renal impairment. MR-proADM level was related to furosemide dose. Patients taking higher doses of diuretics had higher MR-proADM levels. The mean MR-proADM level without furosemide (n = 122) was 0.62 (+/- 0.55) nmol/L, with low dose (n = 113) 1-39 mg/day was 0.67 (+/- 0.30) nmol/L, with mid dose (n = 202) 40-79 mg/day was 0.72 (+/- 0.34) nmol/L, with high dose (n = 58) 80-119 mg/day was 0.85 (+/- 0.40) nmol/L, and with maximum dose (n = 74) &gt;= 120 mg/day was 1.07 (+/- 0.76) nmol/L, p &lt; 0.001. Patients with higher MR-proADM levels were more likely to achieve the primary endpoint at a two-year follow-up (p &lt; 0.001) according to multivariant analysis. Conclusions: Elevated plasma MR-proADM levels in patients with chronic heart failure are associated with an increased risk of death and hospitalization. Higher MR-proADM levels in combination with increased use of loop diuretics reflect residual congestion and are associated with a higher risk of severe disease progression.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30218 - General and internal medicine

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Medicina-Lithuania

ISSN

1010-660X

e-ISSN

1648-9144

Svazek periodika

58

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

LT - Litevská republika

Počet stran výsledku

10

Strana od-do

1477

Kód UT WoS článku

000873135400001

EID výsledku v databázi Scopus

2-s2.0-85140586389